TrialClinical cancer research : an official journal of the American Association for Cancer Research2025

Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial.

Sung Hee Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.